Allogene Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thanks for joining us. We're really pleased to have the Allogene team with us. We have David Chang, President and CEO; and Eric Schmidt; CFO. I'm Salveen Richter, biotechnology analyst at Goldman Sachs.
Questions & Answers
To start, David, you've had a broadening set of data from your allogeneic CAR T portfolio over the last year. How is your understanding of the approach been refined as you -- as yourselves and others have worked here to move candidates forward? And help us understand what's still left to be uncovered or understood about the implementation of allogeneic CAR Ts?
Yes, Salveen, first of all, thanks for hosting Allogene in your conference on your first day, and we are delighted to be here. And today with me is Eric Schmidt, our CFO, who
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |